Previous DTI studies have shown increased FA in patients with fragile X syndrome (51,52), similar to what we observed in 15q11.2 BP1-BP2 deletion carriers, suggesting that these changes could be in part due to disruptions in the CYFIP1-FMRP complex. This evidence concerns the gene IGFBP2 and fragile X syndrome.